PSMA

DIAGNOSTIC_TEST3 trials

Sponsors

National Cancer Institute (NCI), Universitair Medisch Centrum Groningen, Radboud Universitair Medisch Centrum

Conditions

Adenoid cystic carcinoma salivary duct carcinoma salivary gland cancerProstate Cancerfirst diagnosis Prostate cancer

Phase 2

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

CompletedNCT03315871

National Cancer Institute (NCI)Prostate Cancer

Start: 2018-03-20End: 2024-06-04Updated: 2025-06-19

Phase 3

Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomy

Active, not recruitingNL-OMON43099

Universitair Medisch Centrum Groningenfirst diagnosis Prostate cancer

Start: 2020-09-03Target: 20Updated: 2024-02-28

Unknown Phase

68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma

Active, not recruitingNL-OMON44299

Radboud Universitair Medisch CentrumAdenoid cystic carcinoma salivary duct carcinoma salivary gland cancer

Start: 2017-11-13Target: 25Updated: 2024-02-28

Related Papers

Association of baseline microbiome and responders to immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT).

Journal of Clinical Oncology2026-05-28